logo
HIV Tests

HIV Tests

Health Line10 hours ago
Key takeaways
HIV testing is crucial because a significant percentage of Americans living with HIV are unaware of their condition, leading to delayed treatment and potential transmission to others. The CDC recommends routine screenings as part of standard healthcare.
Various tests, including rapid at-home options and laboratory tests, can diagnose HIV by detecting antibodies or the virus itself. Fourth-generation tests can detect HIV earlier than previous versions.
For individuals diagnosed with HIV, ongoing monitoring through CD4 counts and viral load measurements is essential to track the disease's progression and the effectiveness of treatment and to prevent transmission to others.
Why is HIV testing important?
According to the Centers for Disease Control and Prevention (CDC), roughly 1.2 million Americans lived with HIV by the end of 2019. And about 13 percent of people living with HIV do not know they've contracted the virus.
In addition to not getting the treatment they need, they can unknowingly transmit the virus to others. In fact, almost 40 percent of new HIV cases are transmitted by people who are undiagnosed.
The CDC's recommendations for HIV testing advise healthcare professionals to provide routine screenings for HIV as a part of standard care regardless of any risk factors.
Despite these recommendations, many Americans have never been tested for HIV.
Anyone who hasn't been tested for HIV should consider asking their healthcare professional for a test. They can also seek free and anonymous HIV testing at a nearby clinic.
Visit the CDC's GetTested website to find a local testing site.
Who needs HIV testing?
The CDC advises that routine HIV testing should be provided in all healthcare settings, especially if testing for other sexually transmitted infections (STIs) at the same time.
People engaging in behaviors that put them at an increased risk for contracting HIV should be tested at least once a year.
Known risk factors include:
having multiple sexual partners
engaging in sex without a condom or barrier method and without pre-exposure prophylaxis (PrEP)
having partners with an HIV diagnosis
injecting drugs
HIV testing is also recommended:
before a person begins a new sexual relationship
if a person learns that they're pregnant
if a person has symptoms of another sexually transmitted infection (STI)
An HIV infection is now considered a manageable health condition, especially if treatment is sought early.
If a person contracts HIV, early detection and treatment can help:
improve their frame of mind
lower their risk of disease progression
prevent the development of stage 3 HIV, or AIDS
It can also help reduce their risk of transmitting the virus to other people.
The life expectancy of people with an HIV diagnosis who start treatment early is the same as those without the virus. People who know that they've been exposed to HIV should seek care as soon as possible.
In some cases, if they're treated within 72 hours, their healthcare professional may prescribe post-exposure prophylaxis (PEP). These emergency medications may help reduce their chances of contracting HIV after they've been exposed to it.
What tests are used to diagnose HIV?
A number of different tests can be used to check for HIV. These tests can be performed on blood samples or saliva samples. Blood samples can be obtained via an in-office finger prick or a blood draw in a laboratory.
Not all tests require a blood sample or a visit to a clinic.
In 2012, the Food and Drug Administration (FDA) approved the OraQuick In-Home HIV Test. It's the first rapid test for HIV that can be performed at home using a sample from a swab inside your mouth.
If a person thinks they've contracted HIV, it can take anywhere from 1 to 6 months after transmission for a standard HIV test to produce positive results.
These standard tests detect antibodies to HIV rather than the virus itself. An antibody is a type of protein that fights off pathogens.
According to Avert, third-generation HIV tests — which are ELISA tests — can only detect HIV 3 months after exposure to the virus.
This is because it generally takes 3 months for the body to produce a detectable number of antibodies.
Fourth-generation HIV tests, which look for antibodies and the antigen p24, can detect HIV 18 to 45 days after transmission. Antigens are substances that cause an immune response in the body.
According to the Centers for Disease Control and Prevention, 97 percent of people with HIV produce a detectable number of antibodies within 3 months. Although it may take 6 months for some to produce a detectable amount, this is rare.
If a person thinks they've been exposed to HIV, they should tell their healthcare professional. A viral load test that directly measures the virus can be used to detect whether someone has recently acquired HIV.
What tests are used to monitor HIV?
If a person has received an HIV diagnosis, it's important for them to monitor their condition on an ongoing basis.
Their healthcare professional can use several tests to do this. The two most common measures for assessing HIV transmission are CD4 count and viral load.
CD4 count
HIV targets and destroys CD4 cells. These are a type of white blood cell found in the body. Without treatment, the CD4 count will decrease over time as the virus attacks the CD4 cells.
If a person's CD4 count decreases to fewer than 200 cells per cubic millimeter of blood, they'll receive a diagnosis of stage 3 HIV, or AIDS.
Early and effective treatment can help a person maintain a healthy CD4 count and prevent the development of stage 3 HIV.
If treatment is working, the CD4 count should remain level or increase. This count is also a good indicator of overall immune function.
If a person's CD4 count drops below particular levels, their risk of developing certain diseases increases substantially.
Based on their CD4 count, their doctor may recommend prophylactic antibiotics to help prevent these infections.
Viral load
Viral load is a measure of the amount of HIV in the blood. A healthcare professional can measure the viral load to monitor the effectiveness of HIV treatment and the status of the disease.
When a person's viral load is low or undetectable, they're less likely to develop stage 3 HIV or experience its associated immune dysfunction.
A person is also less likely to transmit HIV to others when their viral load is undetectable.
People with undetectable viral loads should still continue to use condoms and other barrier methods during sexual activity to prevent transmission to others.
Drug resistance
A healthcare professional may also order tests to learn if a strain of HIV is resistant to any medications used in treatment. This can help them decide which anti-HIV drug regimen is most appropriate.
Other tests
A medical professional may also use other tests to monitor someone for common complications of HIV or side effects of treatment. For example, they may order regular tests to:
monitor liver function
monitor kidney function
check for cardiovascular and metabolic changes
They may also perform physical exams and tests to check for other illnesses or infections associated with HIV, such as:
A CD4 count below 200 cells per cubic millimeters isn't the only sign that HIV has progressed to stage 3 HIV. Stage 3 HIV can also be defined by the presence of certain opportunistic illnesses or infections, including:
fungal diseases, such as coccidioidomycosis or cryptococcosis
candidiasis, or yeast infection, in the lungs, mouth, or esophagus
histoplasmosis, a type of lung infection
Pneumocystis jiroveci pneumonia, which was previously known as Pneumocystis carinii pneumonia
recurrent pneumonia
tuberculosis
mycobacterium avium complex, a bacterial infection
chronic herpes simplex ulcers, lasting longer than one month
isosporiasis and cryptosporidiosis, intestinal diseases
recurrent salmonella bacteremia
toxoplasmosis, a parasitic infection of the brain
progressive multifocal leukoencephalopathy (PML), a brain disease
invasive cervical cancer
Kaposi sarcoma (KS)
lymphoma
wasting syndrome, or extreme weight loss
Continuing HIV research
As testing advances, researchers are hoping to find pathways to a vaccine or a cure in the coming years.
As of 2020, there are over 40 approved antiretroviral drugs on the market with new formulations and methods being researched all the time.
Current testing only detects markers of the virus as opposed to the virus itself, but research is finding ways the virus can hide in immune system cells. This discovery is allowing for better understanding and more insight into an eventual vaccine.
The virus mutates rapidly, which is one of the reasons it's a challenge to suppress. Experimental therapies such as a bone marrow transplant to treat lymphoma using stem cells are being tested for treatment potential.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AstraZeneca pledges $50bn US investment ahead of drugs tariffs
AstraZeneca pledges $50bn US investment ahead of drugs tariffs

Yahoo

time20 minutes ago

  • Yahoo

AstraZeneca pledges $50bn US investment ahead of drugs tariffs

British pharmaceuticals giant AstraZeneca has revealed it plans to invest $50 billion (£37 billion) in America over the next five years. The commitment came only a week ahead of expected confirmation from Donald Trump of swingeing tariffs of up to 200% on imported drugs The investment will be made in medicines manufacturing and R&D, and create tens of thousands of high skilled jobs, the Cambridge based company said. By 2030 half the company's expected $80 billion of revenues will be generated in the USA. The investments will include a new multi-billion dollar drug substance manufacturing centre focused on chronic diseases in Virginia. It will be the company's biggest commitment to a single facility anywhere in the world. It will produce drug substances for the company's weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The $50 billion investment also includes: Expansion of an R&D facility in Gaithersburg, Maryland; an R&D centre in Kendall Square, Cambridge, Massachusetts; manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California; continuous manufacturing expansion in Mount Vernon, Indiana; and specialty manufacturing expansion in Coppell, Texas Howard Lutnick, US Secretary of Commerce, said: "For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. 'We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here." Governor Glenn Youngkin, Commonwealth of Virginia, said: "I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States. 'This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation's domestic supply chain. 'Advanced manufacturing is at the heart of Virginia's dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth." Pascal Soriot, CEO, AstraZeneca, said: "Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally." The US is AstraZeneca's largest market and home to 19 R&D, manufacturing and commercial sites. The company employs more than 18,000 people and support 92,000 jobs across the United States. The US represents 42% of total revenue. Error in retrieving data Sign in to access your portfolio Error in retrieving data

Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR
Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR

Yahoo

time20 minutes ago

  • Yahoo

Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR

Bispecific T‑cell engagers now dominate oncology pipelines, with global trial activity up 256% since 2019. FDA has approved more than 15 such drugs, and U.S. spending is projected to hit $12.2billion by 2025, rising to over $50 billion by 2032. San Francisco, USA, July 22, 2025 (GLOBE NEWSWIRE) -- The global is witnessing a transformative surge, projected to grow at an impressive compound annual growth rate (CAGR) of 40.10%, reaching a valuation of approximately USD 163,149.35 million by 2032. This extraordinary growth is propelled by the increasing adoption of bispecific antibody therapies in oncology and immunology, groundbreaking clinical outcomes, and robust R&D investments aimed at next-generation biologics. Bispecific antibodies are bioengineered molecules designed to simultaneously recognize and bind to two different antigens or epitopes. Unlike monoclonal antibodies that target a single antigen, bispecific antibodies can link a disease-related antigen (such as one found on cancer cells) to another molecule—often a T-cell—thus redirecting immune cells to attack malignant tissues with heightened precision. This dual-binding capability is unlocking new therapeutic possibilities in cancer, autoimmune diseases, and infectious diseases. As of 2024, over 300 bispecific antibodies are in global clinical development, with 14 already approved by the U.S. FDA, reflecting the sector's rapid growth and clinical validation. Download Free Sample Report PDF @ Global Bispecific Antibodies Market Key Players- Detailed Competitive Insights Amgen Genentech Akeso, Inc. Taisho Pharmaceutical Janssen Immunocore Adimab, Innovent Biologics, Inc. AstraZeneca Affimed GmbH Xencor F. Hoffmann-La Roche Ltd. Sanofi Regeneron Pharmaceuticals Inc. Pieris Pharmaceuticals, Inc. Eli Lilly Mereo BioPharma Group plc Merus MacroGenics, Inc. Sobi, TG Therapeutics Inc. Genmab A/S Alteogen Emergent BioSolutions Inc. Novartis AG Astellas Pharma Inc. Celgene Corporation Others Market Drivers 1. Increasing Cancer Prevalence Globally Cancer remains a global health crisis, with the World Health Organization (WHO) estimating around 19.3 million new cancer cases and nearly 10 million deaths in 2023 alone. Traditional therapies are often limited by poor specificity and severe side effects, which have shifted the focus toward more targeted modalities, such as bispecific antibodies. Their unique mechanism allows precise tumor targeting while preserving healthy tissues, making them a preferred choice for next-gen cancer therapies. 2. Regulatory Approvals and Accelerated Development Pathways The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have actively supported innovative antibody therapeutics. Between 2022 and 2024, the FDA approved six bispecific antibodies, a testament to their growing clinical value. Regulatory agencies are also introducing expedited pathways for breakthrough therapies, speeding up market entry for promising candidates. 3. Rising Investments in Immunotherapy and Biologics Governments and private players are significantly boosting funding for immunotherapy research. For instance, the U.S. National Cancer Institute (NCI) allocated over USD 15 billion toward cancer research in 2023, a portion of which is directed toward the development of targeted therapies, including bispecific antibodies. This capital influx is catalyzing clinical trials, molecule discovery, and scalable manufacturing solutions. Market Challenges Despite the optimistic trajectory, the bispecific antibodies market faces notable challenges: Complex Manufacturing: Producing bispecific antibodies involves intricate processes, such as protein folding and stability optimization, which increase production time and cost. High Development Costs: The R&D cycle for bispecific therapies is long and resource-intensive, often requiring large-scale trials and advanced biotechnological platforms. Immunogenicity Risks: Some bispecific formats can trigger unwanted immune responses, complicating their clinical profiles. Nonetheless, advances in antibody engineering, such as the development of Fc-engineered antibodies and T-cell engaging bispecifics (BiTEs), are helping overcome these limitations. Regional Insights North America is poised to maintain a dominant position in the global bispecific antibodies market. Its leadership is driven by: A well-established biotech and pharma industry. Substantial government and private R&D investments. Early and streamlined regulatory approvals. In 2023 alone, the U.S. government dedicated nearly USD 7.9 billion toward cancer research, a portion of which supports novel antibody-based treatments. Moreover, the presence of major biopharmaceutical companies and academic research centers ensures rapid clinical development. Asia-Pacific, on the other hand, is anticipated to experience the fastest growth rate. Countries such as China, India, and South Korea are: Increasing healthcare expenditures. Encouraging local biotech innovation. Expanding access to clinical trials and biologic therapies. China, for example, is investing heavily in biologics manufacturing capabilities and has introduced supportive regulations for fast-track drug approval, which will likely make the region a future hub for bispecific antibody development. TABLE OF CONTENT 1. Bispecific Antibodies Market Overview 1.1. Study Scope 1.2. Market Estimation Years 2. Executive Summary 2.1. Market Snippet 2.1.1. Bispecific Antibodies Market Snippet by Drug Type 2.1.2. Bispecific Antibodies Market Snippet by Indication 2.1.3. Bispecific Antibodies Market Snippet by Distribution Channel 2.1.4. Bispecific Antibodies Market Snippet by Country 2.1.5. Bispecific Antibodies Market Snippet by Region 2.2. Competitive Insights 3. Bispecific Antibodies Key Market Trends 3.1. Bispecific Antibodies Market Drivers 3.1.1. Impact Analysis of Market Drivers 3.2. Bispecific Antibodies Market Restraints 3.2.1. Impact Analysis of Market Restraints 3.3. Bispecific Antibodies Market Opportunities 3.4. Bispecific Antibodies Market Future Trends…… Get a detailed analysis on regions, market segments, customer landscape, and companies@ Market Segmentation by Indication The bispecific antibodies market is segmented by application into: Cancer Autoimmune and Inflammatory Disorders Others Among these, the oncology segment is forecasted to command the largest share throughout the forecast period. As of March 2025, over 650 bispecific antibodies are in clinical development globally—nearly all focused on oncology applications, and nine of the 11 bispecifics approved since 2021 target cancer, representing over 80% of recent regulatory approvals. Competitive Landscape & Innovation Strategies The bispecific antibody space is rapidly evolving with heightened competition among biotech giants and emerging players. Leading companies are prioritizing: Next-generation platforms for greater safety, flexibility, and efficacy. Strategic collaborations and licensing deals to expand pipeline access. Geographic expansion into emerging economies with rising healthcare demands. Biotech firms are utilizing AI-driven drug discovery, cell-line optimization, and novel bispecific formats (like dual-variable domain antibodies and knob-into-hole technologies) to advance their products. Some players are also entering into co-development agreements to reduce costs and accelerate regulatory milestones. Future Outlook The bispecific antibodies market is positioned at the forefront of immunotherapeutic innovation. With strong clinical potential, increasing funding, and a favorable regulatory climate, the sector is expected to witness substantial growth through 2032. As manufacturing bottlenecks are resolved and newer formats with improved safety emerge, bispecific antibodies will likely become standard components of combination therapies in oncology and immune-related disorders. In conclusion, the bispecific antibodies market offers immense opportunities for stakeholders across biotechnology, healthcare, and investment sectors. Its rapid evolution signals a paradigm shift in how complex diseases are treated, ushering in a new era of precision medicine. Browse more Reports from AnalystView Market Insights:CONTACT: U.S. Office: 11923 NE Sumner St STE 750924 Portland, Oregon, 97220, USA Phone: +1 615-326-5253 (U.S. Toll Free) Email: mayank@ Email: inquiry@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

More Than a Number: Sleep Quality Next Target for CV Health
More Than a Number: Sleep Quality Next Target for CV Health

Medscape

time21 minutes ago

  • Medscape

More Than a Number: Sleep Quality Next Target for CV Health

From the Dalai Lama's claim that it is the 'best meditation' to Benjamin Franklin's insistence that it makes a person 'healthy, wealthy, and wise,' a good night's sleep has long been touted as the secret to a healthy life. And the American Heart Association (AHA) agrees. In 2022, the AHA added sleep duration to Life's Simple 8, their checklist for optimal heart health. This was on the basis of strong evidence from epidemiologic studies linking sleep duration to poor cardiometabolic outcomes, such as obesity, type 2 diabetes, and stroke. But emerging research suggests that it's time for cardiologists to consider more than just sleep duration. 'Lack of sleep has been long known to be associated with coronary heart disease,' said Martha Gulati, MD, the director of Preventive Cardiology in the Smidt Heart Institute at Cedars-Sinai, in Los Angeles. Gulati emphasized that achieving adequate sleep (between 7 and 9 hours) has also been associated with healthy traits, such as better blood pressure, better cholesterol control, and healthy weight. Martha Gulati, MD However, the number of hours a person sleeps each night just scratches the surface she said. Research has shown that consistency and preferred timing of sleep, known as sleep chronotype, are important as well. In a 2023 UK-based study, middle-aged adults who considered themselves night owls — the evening sleep chronotype — had signs of potentially detrimental cardiac remodeling on cardiac magnetic resonance imaging compared with morning folks. And the damage may start early. In a recent study in adolescents, shorter sleep duration was associated with adverse markers of left ventricular wall remodeling and liver fat accumulation suggesting a cumulative effect on health, according to the authors. The MESA Sleep Ancillary study found that people with greater irregularity in sleep patterns — such as falling asleep at different times each night — had a higher coronary artery calcium burden than those with more regular sleep patterns. Because sleep is associated with a range of cardiometabolic diseases, Julie Marcus, MD, a cardiologist at Weill Cornell Medicine/New York Presbyterian Hospital, New York City, said addressing poor sleep has become an important but underappreciated aspect of maintaining a healthy heart. Julie Marcus, MD She added that patients also need to be aware that poor sleep can affect their health and what the various components of healthy sleep are. 'Beyond saying do you snore [or] stop breathing at night and do you sleep between 7 and 9 hours, there's so much more to sleep that is important,' Marcus said. Expanding the Definition of Sleep Health Early this year, the AHA published an updated scientific statement that addresses multidimensional sleep health. This includes duration, timing, regularity, sleep-related daytime functioning, satisfaction, continuity — the ability to initiate and maintain sleep — and sleep architecture, or the amount and timing of the various sleep stages. Marie-Pierre St-Onge, PhD, a sleep health researcher and lead author of the AHA statement, explained that it was developed to promote the breadth of new research. 'We want to let people know that sleep is more than just how long you sleep at night,' said St-Onge, who is the director of the Center of Excellence for Sleep and Circadian Research at Columbia University, New York City. Marie-Pierre St-Onge, PhD For example, she explained excessive daytime sleepiness has been associated with cardiovascular disease, coronary heart disease, stroke, and all-cause mortality. Similarly, sleep disturbances have been linked to hypertension, arterial stiffness, and coronary heart disease. Understanding Poor Sleep's Mechanism of Action St-Onge emphasized that new research has also increased understanding around the associations between poor sleep and worsening cardiometabolic outcomes. Her research has shown that sleep restriction increases oxidative stress in the lining of the arteries that could lead to endothelial dysfunction. Short sleep also impairs the body's ability to counteract this oxidative stress. 'We see immune suppression from poor sleep duration and poor sleep quality,' St-Onge said. In addition, we have found links between sleep regularity and eating patterns, St-Onge noted. Gulati believes that the AHA statement represents an opportunity to raise awareness among patients, cardiologists, and clinical researchers about the importance of better understanding these causal effects of poor multidimensional sleep health. 'I think it is also a call to action to improve the assessment of sleep, particularly in research so we can rigorously assess these components,' Gulati said. 'We need to know what interventions can improve components of sleep as well, and their effect on cardiovascular health. Those knowledge gaps need to be closed.' Talking About Sleep Health Those knowledge gaps are why the statement did not offer guidance for clinical approaches, but St-Onge emphasized the importance of educating and discussing this topic with patients now. She recommended asking an open-ended question: 'How's your sleep?' 'That opens up a conversation for people to express exactly what's bothering them with their sleep.' For example, she said, 'It may be they get plenty of hours of sleep, but they lie there awake for way too long, or they're having a hard time falling asleep, or they get a lot of sleep, but they still wake up not feeling refreshed during the day.' Starting the conversation — and documenting it in clinical notes — will be the first step to helping patients with poor sleep health, she said. Marcus agreed that cardiologists should make time to discuss sleep health with patients, even though it can be more complicated than addressing cholesterol or blood pressure because 'sleep is not a number.' Still, she said that understanding a patient's poor sleep health can also provide physicians with new modifiable risk factors for improving their cardiovascular health. 'Sleep is the next target,' Marcus said. 'We know it impacts health, and it's just a matter of how do we screen for it.' Gulati reported financial relationships with Boehringer Ingelheim Pharmaceuticals, Medtronic, Merck & Co., New Amsterdam, and Zoll.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store